1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Verge Genomics Announces Milestones in Collaboration with Eli Lilly Regarding ALS

22 Nov 2024
Admin
News Article

Verge Genomics Announces Milestones in Collaboration with Eli Lilly Regarding ALS

Verge Genomics announces milestones in collaboration with Eli Lilly to discover and develop novel treatments for ALS

Overview

Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced that Eli Lilly & Company (Lilly) has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) as part of the companies’ collaboration, which was initiated in July 2021. The targets were identified and validated by Verge’s AI-enabled CONVERGE platform, with 83% of prioritized targets validated in disease-relevant models, a rate significantly higher than industry standards, demonstrating the robust predictive power of CONVERGE. Target selection triggered near-term milestone payments from Lilly to Verge. Verge is eligible for additional downstream economics as the programmes progress.

From Neurodegeneration and Genetic Medicine at Lilly

“By providing us with scientifically compelling target predictions, which were supported by elegant validation experiments in human cell systems, the Verge team and CONVERGE platform have delivered multiple promising therapeutic targets,” said Michael Hutton, Ph.D., senior vice president and CSO, Neurodegeneration and Genetic Medicine at Lilly.
“We look forward to building upon their work with the aim of advancing ALS drug candidates to address the significant unmet patient needs in this fatal disease.”

The 3-year Collaboration

In 2021, Verge and Lilly entered into a 3-year collaboration to discover and validate novel therapeutic targets for ALS that would become the focus for subsequent drug discovery and development.
Verge received up to $25 million in upfront, equity investment and potential near-term milestones, with a total deal value of $694 million plus potential downstream royalties.

From the CSO: Verge Genomics

“This achievement further validates the predictive power of CONVERGE to unlock unique insights into the biological underpinnings of ALS and discover meaningful targets for complex diseases,” said Robert H. Scannevin, Ph.D., chief scientific officer at Verge Genomics.
“By combining robust computational predictions with compelling experimental data, we empowered Lilly to advance selected targets into further development.”

Verge: Focus on VRG50635

Verge also continues to advance VRG50635, its internal lead drug candidate for the treatment of sporadic and familial ALS.
VRG50635 is currently being evaluated in a phase 1B Proof-of-Concept (PoC) study in Canada and several European countries.
Enrollment is complete and dose escalation, including to the highest dose level, is ongoing.
Verge’s PoC study incorporates innovative technology that collects dense amounts of unbiased, objective, disease-relevant molecular and clinical data to properly assess safety, tolerability, pharmacological dose-response, and efficacy, including for disease modification.
VRG50635 is a potent, orally bioavailable and brain-penetrant PIKfyve inhibitor shown to improve survival in ALS patient-derived motor neurons and has shown efficacy in multiple preclinical studies in ALS-relevant models of motor neuron degeneration.

Verge is focused on developing therapeutics for complex diseases with high unmet need, using human genomics from patient disease tissues and machine learning.